Hypersensitivity Reactions and the Utility of Oral and Intravenous Desensitization in Patients with Gynecologic Malignancies

Robinson, Jubilee B.; Singh, Diljeet K.; Bodurka, Diane C.; Jt, Wharton; Gershenson, David M.; Wolf, Judith K.

doi:10.1006/gyno.2001.6331

Cited by 103 publications

(76 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A hypersensitivity reaction can occur either during (acute reaction) or following (delayed reaction) administration of a chemotherapeutic agent. Symptoms may include, but are not limited to, flushing, alterations in heart rate and blood pressure, dyspnea/bronchospasm, back pain, chest discomfort, fever, pruritis, erythema, nausea, and rash [5,6]. The precise mechanisms responsible for hypersensitivity reactions are currently unknown.…”

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

“…In contrast to what occurs with taxanes, premedication with steroids and antihistamines may not prevent hypersensitivity reactions to platinum-containing agents [8]. Hypersensitivity reactions to platinum-containing compounds are thought to be mediated by IgE and/or the direct release of vasoactive substances [5]. The results of intradermal skin tests with carboplatin have been shown to be fairly reliable predictors of hypersensitivity reactions to the drug [6].…”

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

“…Desensitization protocols have been successfully used to manage hypersensitivity reactions to paclitaxel and platinum-containing compounds [5,8]. Based on a carboplatin desensitization protocol developed by Windom et al [14], Goldberg et al [8] reported the success of a desensitization regimen in two patients that involved administration of increasing concentrations of carboplatin over a prolonged period of time.…”

Section: Desensitization Protocolsmentioning

confidence: 99%

See 2 more Smart Citations

Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol

Gammon¹,

Bhargava

McCormick

2004

The Oncologist

View full text Add to dashboard Cite

Oxaliplatin (Eloxatin ® ; Sanofi-Synthelabo Inc.; New York, NY) is a third-generation platinum agent indicated for the treatment of colorectal cancer. Severe hypersensitivity reactions to oxaliplatin rarely occur; however, they do represent a threat to the small number of patients that are occasionally affected. We developed a desensitization protocol and successfully applied it to a patient with severe, grade 3, hypersensitivity to oxaliplatin. For patients who have mild sensitivity to oxaliplatin, slowing the run rate down and giving an antihistamine and/or a steroid usually suffice. Desensitization will help to provide the small number of patients who experience severe hypersensitivity reactions with the ability to further receive an effective therapy for their colorectal cancer. The desensitization protocol is described in detail. The Oncologist

show abstract

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

Section: Desensitization Protocolsmentioning

confidence: 99%

See 1 more Smart Citation

Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol

Gammon¹,

Bhargava

McCormick

2004

The Oncologist

View full text Add to dashboard Cite

show abstract

“…In cancer therapy, chlorpheniramine, an antihistamine, can be used to treat hypersensitivity to cytostatic and cytotoxic drugs (7). Antihistamines can also be used as adjuncts in the treatment of cancer pain, as they have analgesic effects (8).…”

Section: Introductionmentioning

confidence: 99%

A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: Tumor response and its correlation with clinical benefit response, and preliminary quality of life data

Scheele¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. This pilot study of Auron Misheil Therapy (AMT) in women with advanced cervical cancer was an open-label, single arm study to collect initial safety, efficacy, and quality of life data. Fifteen women with stage IIIb or IVa cervical cancer were given twice daily intramuscular injections of AMT (insulin, chlorpheniramine and camomile extract) for 3 months. Objective tumor response was evaluated using CT scans and analyzing the data according to the WHO RECIST criteria.

show abstract

“…Antihistamines are used as supportive cancer medication to alleviate cancer pain (11). It has also been shown that, like insulin, antihistamines have a chemotherapy sensitizing effect on tumor cells (12,13). In addition to this well-established function, it has been demonstrated that chlorpheniramine has anti-tumorigenic potential.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor effects of AMT in the renal cell carcinoma model

Drevs¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Auron-Misheil-Therapy (AMT) is a defined but unique combination of approved pharmaceuticals. It consists of insulin, chlorpheniramine and an aqueous camomile extract, and it has been successfully applied clinically in late-stage cancer patients. The purpose of this study was to elucidate the anti-tumor efficacy of AMT in a validated murine renal cell carcinoma animal model (RENCA). There were two independent studies; each animal group consisted of 16 mice. During a 6-week pretreatment period, vehicle (group A) and AMT (1.6 mg/kg/d) (group B) were administered once daily in a 5 days/week schedule either intramuscularly or subcutaneously. Tumor challenge at day 0 was followed by a 3-week treatment period (either vehicle or AMT once daily intramuscularly for 21 days consecutively). In study 2 the AMT dosage was increased up to 4-fold by doubling individual doses and switching to a twice daily schedule. The injections were all intramuscular. With the exception of group D, a six-week pretreatment period preceded the tumor challenge at day 0. Tumor challenge was followed by a 3-week treatment period (vehicle, AMT at either 3.2 mg/kg/d) (group A) or 6.4 mg/kg/d (group B), or AMT 0 , an AMT preparation which does not stimulate IL-6 secretion (6.4 mg/kg/ d, group C) continuously for 21 days. AMT administration for group D (6.4 mg/kg/d) was limited to the treatment period from day 1 to 21. All mice were sacrificed 21 days after tumour transplantation. AMT administration was safe and well tolerated, and significantly reduced primary tumor volume in pretreated animals. The effective route of application was intramuscular, with dose escalation resulting in an improved anti-tumor effect. This is the first demonstration of a significant anti-tumorigenic effect of AMT in a validated tumor model.

show abstract

Hypersensitivity Reactions and the Utility of Oral and Intravenous Desensitization in Patients with Gynecologic Malignancies

Cited by 103 publications

References 42 publications

Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol

Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol

A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: Tumor response and its correlation with clinical benefit response, and preliminary quality of life data

Anti-tumor effects of AMT in the renal cell carcinoma model

Contact Info

Product

Resources

About